Germany - Drugs
For more information and to make a bid you will need to go to the third party website.
Details
Provided by![Open Opps](/export-opportunities/assets/logos/openopps_logo-1546c8f66e3418f395e7a287754763e11a1e785288e4c271cb874028ff585dc1.png)
- Opportunity closing date
- 29 July 2024
- Opportunity publication date
- 22 August 2022
- Category
- 33600000: Ph
- Value of contract
- to be confirmed
- Your guide to exporting
Description
The subject of this publication is the conclusion of non-exclusive discount agreements pursuant to Section 130a (8) SGB V for drugs containing the active ingredient interferon beta-1a (ATC: L03AB07 - for subcutaneous use) within the framework of a so-called "open-house model". All suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the opportunity to conclude or join a discount agreement in accordance with Section 130a (8) of the German Social Code, Book V for the active ingredients listed in Section B, subject to uniform contractual conditions and a uniform access procedure. Interested pharmaceutical companies can request the participation documents and the respective contract from the contact address mentioned under I.1). A prerequisite for the conclusion of an agreement is that the interested pharmaceutical company submits the requested participation documents completely filled out and signed.
Conclusion of non-exclusive discount agreements in accordance with Section 130a (8) of the German Social Code, Book V for drugs with the active ingredient Interferon beta-1a (ATC: L03AB07 - for subcutaneous use) with the option of concluding an agreement at any time as part of a so-called "open-house model". A contract will be concluded with each pharmaceutical company that meets the participation requirements. There is no exclusivity and the contract can be concluded at any time and under the same conditions. Individual contract negotiations are not carried out. The earliest start of the contract is 01.10.2022.Based on this, the contract period is a maximum of 24 months. The contract ends on 30.09.2024 regardless of the start date. Should AOK Saxony-Anhalt invite tenders for exclusive contracts for the active ingredients during the term of the contract in accordance with the relevant provisions of public procurement law, the contracts concluded in the context of this publication will be terminated in accordance with the contractual provisions.This publication does not constitute the award of a public contract within the meaning of Section 103 GWB or public procurement law. In order to ensure the greatest possible degree of transparency for the intended contract conclusions, the publication is made in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice is used. The resulting conceptual specifications, such as the procedural designation "open procedure", are solely due to the use of this publication form and the publication platform. Any further meaning, in particular a submission to procurement law regulations, insofar as they are not obligatory for legal reasons, is not associated with this.
- Opportunity closing date
- 29 July 2024
- Value of contract
- to be confirmed
About the buyer
- Address
- AOK Sachsen-Anhalt Lüneburger Str. 4 Magdeburg 39106 Germany
- Contact
- openhouse@san.aok.de
The deadline to apply for this opportunity has passed.
Visit the
opportunities page
to find another.